Trial Profile
A Phase 1b Clinical Trial to Evaluate Mucosal Immune Responses to a DNA Plasmid Vaccine Prime Followed by an HIV-1 Adenoviral Vector Boost in Healthy Adenovirus Type 5 Seronegative HIV-1-uninfected Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs VRC-HIVADV014-00-VP (Primary) ; VRC-HIVDNA016-00-VP (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- 05 Mar 2018 Status changed from active, no longer recruiting to completed.
- 17 Jan 2012 Actual initiation date (May 2011) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.